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peripheral nerve block in rats.
Methods: Forty male Sprague–Dawley rats were randomly divided into 5 experimental groups: Group 1,
sham; Group 2, perineural levobupivacaine (0.2 mL of a 0.5% solution) and subcutaneous saline; Group 3,
perineural levobupivacaine (0.2 mL of a 0.5% solution) plus dexmedetomidine (20 mg/kg dexmedetomi-
dine) and subcutaneous saline; Group 4, perineural saline and subcutaneous dexmedetomidine; and
Group 5, perineural saline and subcutaneous saline. Pain reﬂexes in response to a thermal stimulus were
measured at 0 and 240 minutes after drug administration by using a hot-plate and tail-ﬂick tests.
Neurobehavioral status, including sensory and motor functions, was assessed by an investigator who was
blinded to the experimental groups every 30 minutes until normal functioning resumed.
Results: The sensory and motor blockades of the rats did not increase in the treatment with
dexmedetomidine plus levobupivacaine when compared with the treatment with levobupivacaine alone
at all the time points (P 4 0.05). Compared with rats in Group 2, those in Group 3 showed signiﬁcantly
higher latency times at 30 and 60 minutes in the hot plate test (P o 0.01). At 30 and 60 minutes, the
latency times of the rats in Group 3 were longer than those in Group 2 in the tail-ﬂick test (P o 0.01).
Furthermore, the durations of the complete sensory and motor blockade were similar when treatment
with levobupivacaine plus dexmedetomidine was compared with treatment with levobupivacaine alone.
Conclusions: A 20mg/kg dose of dexmedetomidine added to levobupivacaine did not increase the
duration of the sensory and motor blockades in rats. However, treatment with dexmedetomidine plus
levobupivacaine increased the quality of analgesia in rats.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Single injections of local anesthetics have been used in regional
anesthesia and peripheral nerve blocks worldwide for many years.
Long-lasting anesthetic solutions such as bupivacaine, levobupiva-
caine, and ropivacaine provide analgesia for approximately 6 to14r Inc.
dogan, MD, Department of
School of Medicine, Elazig
S. Aydogan).
Open access under CC BY-NC-Nhours.1 Postoperative pain may continue for several days, disrupt-
ing a patient’s comfort and increasing the demand for opioids,
which have very serious side effects. Because the analgesic effect of
local anesthetics is very short, and prolonged block duration is
essential for patients who have postoperative pain,2 local anes-
thetics may be combined with other drugs to extend the duration
of the block, and indwelling catheters may be used for administer-
ing them. Generally, the use of indwelling catheters is inconvenient
except for administering drugs to the epidural space.3
Levobupivacaine is an S(-)-enantiomer of racemic bupivacaine and
is a local anesthetic that is currently used in clinical practice.
Levobupivacaine exhibits lesser cardiotoxicity and central nervous
system (CNS) toxicity than that by R(þ)-bupivacaine.4 Levobupiva-
caine is widely used in spinal and epidural anesthesia and in supra-
clavicular nerve blocks.5 In addition, many clinical studies have
shown that clonidine extends the duration of peripheral nerveD license.
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thought the blockade is caused by local vasoconstriction
or inhibition of impulse conduction in the peripheral nerves.8 Addi-
tionally, α2-adrenoceptor agonists exhibit antinociceptive properties.9
Dexmedetomidine exerts speciﬁc and selective α2-adrenoceptor
effects.10 Moreover, dexmedetomidine has been shown to be safe
and effective in central and peripheral blockades in human beings11,12
and has been widely used to achieve sedation in intensive care
units.13 Several studies have tested the addition of dexmedetomidine
to local anesthetics in sciatic nerve blocks in rats to deter-
mine if the addition enhanced the duration of sensory and motor
blockades.1,14–16 For instance, Brummett et al1 investigated the
combined administration of dexmedetomidine and ropivacaine in
sciatic nerve block in rats. They reported that dexmedetomidine
added to ropivacaine increased the duration of sensory blockade.
Another study also by Brummett et al16 showed that the duration of
complete sensory and motor blockades were lengthened in dexme-
detomidine and bupivacaine groups. However, in those studies the
authors evaluated these effects only through neurobehavioral tests,
such as motor functions and sensory response, and observation of
histopathology.
In our study we investigated the effects of perineural and
intraperitoneal administration of levobupivacaine plus dexmede-
tomidine in sciatic peripheral nerve block in rats through the use
of neurobehavioral tests and analgesia measures such as hot-plate
and tail-ﬂick tests.Methods
Animals
We obtained 40 male Sprague–Dawley rats weighing between
210 g and 240 g from Inonu University Laboratory Animals
Research Center, Malatya, Turkey. The rats were maintained in a
room at a temperature of 211C (721C) and relative humidity of
60% (75%) under a 12-hour light/dark cycle. The animals were
housed in plastic cages (50  35  20 cm, 8 animals per cage).
The experiments were performed according to the standards of
animal research issued by the National Health Research Institute
and with the approval of the Inonu University Ethical Committee.
Drug administration
Levobupivacaine 1% solution was mixed with normal saline or
dexmedetomidine to obtain ﬁnal concentrations of 0.5% levobupi-
vacaine and 0.5% levobupivacaine plus 0.005% dexmedetomidine.
In addition, 0.01% dexmedetomidine was mixed with normal
saline to obtain 0.005% dexmedetomidine. All dexmedetomidine
doses were determined on the basis of the weights of the
individual rats (20.0 mg/kg), with a ﬁnal mean (SD) concentration
of 119.3 (4.5) mmol/L.16
Experimental design
The rats were randomly divided into 5 groups consisting of
8 animals in each group: Group 1, sham; Group 2, perineural
levobupivacaine (0.2 mL of a 0.5% solution) and subcutaneous
saline; Group 3, perineural levobupivacaine (0.2 mL of a
0.5% solution) plus dexmedetomidine (20 mg/kg dexmedetomi-
dine) and subcutaneous saline; Group 4, perineural saline
and subcutaneous dexmedetomidine; Group 5, perineural saline
and subcutaneous saline. The dosage of dexmedetomidine
was chosen according to previous dose–response study by
Brummett et al.14Perineural sciatic nerve injection
An investigator blinded to the experimental drug conditions
performed the sciatic nerve injections. Another investigator per-
formed the subsequent neurobehavioral tests, and the laboratory
assistants prepared the drugs. Rats without any signs of preproce-
dural neurobehavioral impairment were anesthetized using an
intraperitoneal administration of 10 mg/kg ketamine (Ketalar;
Pﬁzer, Istanbul, Turkey) and 10 mg/kg xylazine (Rompun; Bayer,
Toronto, Canada). The sciatic nerve of the right hind limb was
exposed using a lateral incision over the thigh and division of the
superﬁcial fascia as previously described.14,15 After the dissection,
the sciatic nerve was identiﬁed at the point proximal to its
bifurcation. Using a tuberculin syringe, 0.2 mL of the drug was
injected into the perineural space. Following the perineural injec-
tion, 0.2 mL of the drug was subcutaneously injected into the fold
of the skin at the back of the neck. A nonabsorbable muscle fascia
suture was performed at the midpoint of the injection site as a
marker for subsequent nerve removal. The suturing was performed
in the muscle fascia of the biceps femoris below the subcutaneous
tissue, and the sutures neither directly touched nor surrounded
the nerve. All the incisions were closed. Eight intervals
(0–240 minutes) from both the operative and control were
obtained every 30 minutes from the time of injection. This interval
was chosen according to previously related-studies.1,14
Measurement of analgesia
Acute thermal pain was determined using hot-plate and tail-
ﬂick tests, which are 2 established methods for measuring thermal
analgesia in rodents.
Experimental procedures of the hot-plate test
The surface of the hot plate (Columbus Instruments, Columbus,
Ohio) was heated to achieve a constant temperature of 501C
(70.51C), which was conﬁrmed using a built-in digital thermom-
eter. The time (in seconds) between the placement of the rats on
the plate and the onset of shaking, paw licking, and jumping off
the plate was recorded as the response latency. To avoid tissue
damage, 60 seconds was set as the cut-off time after which the rats
were returned to their cage, regardless of whether a response was
observed.17 The baseline was considered as the mean response
times obtained at 0 and 30 minutes before drug administration
and was deﬁned as the normal response of the animal to the
temperature stimulus. Latency during the hot plate test was
measured at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes
after drug injection. No further nociceptive thresholds were
measured until full recovery from the effects of the general
anesthetic was achieved.
Experimental procedures in the tail-ﬂick test
Antinociception and thermal analgesia were assessed using the
radiant heat tail-ﬂick test apparatus (Type 812; Columbus Instru-
ments) as previously described.18 Brieﬂy, the rats were placed in
transparent hard plastic tubes, and 3 independent tests were
performed (within a 15-second interval) at each time point. The
mean tail-ﬂick latency was obtained from the measurements of
3 predrug trials, which represented the individual baseline latency.
Animals demonstrating tail-ﬂick latencies ranging from 2 to 5 sec-
onds before the drug treatment were used in the experiments.
Immediately after the baseline assessment, either drugs or saline
were injected into the rats according to the experimental protocol.
The responses were measured at 0, 30, 60, 90, 120, 150, 180, 210,
and 240 minutes after treatment by applying pressure using an
Table II
Tail-ﬂick latency time results, by treatment group.*
Time (min) Group 1
(n ¼ 8)
Group 2
(n ¼ 8)
Group 3
(n ¼ 8)
Group 4
(n ¼ 8)
Group 5
(n ¼ 8)
P Value
Median sec (minimum–maximum)
Basal 8 (3–11) 9 (5–11) 8 (3–12) 8 (3–11) 8 (6–10)
30 5 (4–15) 4 (3–7) 8 (5–15)† 5 (4–10) 4 (3–11) 0.0019
60 5 (5–12) 5 (4–11) 8 (4–15)† 4 (3–12) 5 (4–10) 0.0075
90 5 (3–8) 3 (3–11) 7 (3–14) 4 (2–8) 4 (3–11) NS
120 5 (3–8) 5 (3–11) 3 (3–11) 5 (2–8) 4 (3–11) NS
150 3 (2–15) 4 (3–10) 4 (3–7) 4 (4–10) 4 (3–11) NS
180 6 (2–15) 6 (4–15) 5 (4–13) 4 (3–12) 5 (4–10) NS
210 4 (3–8) 4 (3–9) 4 (3–7) 4 (3–8) 4 (3–7) NS
240 3 (1–6) 3 (2–6) 4 (12–19) 5 (2–9) 4 (2–6) NS
NS ¼ Not signiﬁcant.
n Group 1: sham, Group 2: perineural levobupivacaine (0.2 mL 0.5% solution) and
subcutaneous saline, Group 3: perineural levobupivacaine (0.2 mL 0.5% solution) plus
dexmedetomidine (0.2 mL 0.5% levobupivacaine þ 20 mg/kg dexmedetomidine) and
subcutaneous saline, Group 4: perineural saline and subcutaneous dexmedetomidine,
Group 5: perineural saline and subcutaneous saline.
† Group 2 versus Group 3 (Po0.01).
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was established at 10 seconds to avoid tissue damage. The timing
of the drug injections was adjusted according to that previously
described from related studies in rodents.19,20
Neurobehavioral examination
Sensory functions were evaluated by the withdrawal response
of the paw to a forceps pinch on the lateral foot/toe. The pinch was
limited to a maximum of 1 second to avoid direct paw tissue
trauma. The rats were able to withdraw the tested paw in response
to pain.21,22 The sensory responses were evaluated on the basis of
the withdrawal reﬂex or vocalization to the pinch and scored as
follows: vigorous paw withdrawal response to pinch (normal
sensory function) ¼ 0, moderate withdrawal ¼ 1, minimal with-
drawal ¼ 2, and full sensory block/no response to pinch ¼ 3.23–25
Similarly, the motor function was assessed using the 0 to 3 scale as
follows: normal motor function ¼ 0, normal dorsiﬂexion ability
and walking with curled toes ¼ 1, moderate dorsiﬂexion ability and
walking with curled toes ¼ 2, and no dorsiﬂexion ability and
walking with curled toes ¼ 3.21,22 The sensory and motor functions
were evaluated every 30 minutes by an investigator blinded to the
experimental groups until the blockade was completely recovered.
Statistical analyses
For detecting even minor effects, the required sample sizes used
in this experiment were identiﬁed using statistical power analysis.
The sample sizes necessary for a power of 0.80 were estimated using
NCSS software. Data were analysed using the SPSS software program
for Windows (version 18.0, 2010; IBM Corp, Armonk, New York). The
data were presented as the median (minimum–maximum).
The assumption of a normal distribution was conﬁrmed using the
Kolmogorov–Smirnov test. The Kruskal–Wallis H-test was used when
the assumption of normality was not provided. The Mann–Whitney
U test with Bonferroni’s correction was used for multiple compar-
isons. The statistical signiﬁcance was established at P o 0.01.Results
Measurement of analgesia
Compared with Group 2, rats in Group 3 showed signiﬁcantly
increased latency times at 30 and 60 minutes during the hot plate
test (Table I) (P o 0.01). At 30 and 60 minutes, the latency timesTable I
Hot-plate test latency time results, by treatment group.*
Time (min) Group 1 (n ¼ 8) Group 2 (n ¼ 8) Group 3 (
Median sec (minimum–maximum)
Basal 13 (7–17) 12 (8–15) 10 (9–13)
30 15 (11–22) 20 (12–24) 25 (14–29
60 15 (7–24) 20 (11–25) 24 (13–28
90 14 (11–23) 17 (13–24) 17 (12–25
120 13 (8–23) 13 (8–23) 15 (10–25
150 13 (11–18) 12 (10–24) 15 (12–23
180 14 (8–17) 15 (11–20) 16 (12–24
210 14 (7–19) 13 (11–19) 14 (10–22
240 13 (11–16) 12 (11–16) 14 (12–19
NS ¼ Not signiﬁcant.
n Group 1: sham, Group 2: perineural levobupivacaine (0.2 mL 0.5% solution) and su
dexmedetomidine (0.2 mL 0.5% levobupivacaine þ 20 mg/kg dexmedetomidine) and sub
Group 5: perineural saline and subcutaneous saline.
† Group 2 versus Group 3 (P o 0.01).of the Group 3 rats were longer than those of the Group 2 rats in
the tail-ﬂick test (Table II) (P o 0.01). The results of the tail-ﬂick
and hot plate tests obtained at 30 and 60 minutes showed that the
analgesic effect was better in the Group 3 rats (relative to the
control group) than in the Group 2 rats.
Neurobehavioral results
No rats in Group 1 and Group 5 showed complete sensory or
motor blocks. Dexmedetomidine combined with levobupivacaine
did not enhance the sensory blockade when compared with
levobupivacaine alone at all the time points (Table III). Moreover,
dexmedetomidine and levobupivacaine did not enhance motor
blockade when compared with levobupivacaine alone at all the
time points (Table IV). Furthermore, the durations of the complete
sensory blockade (sensory score ¼ 3) and motor blockade (motor
score ¼ 3) were similar when treatment with levobupivacaine
plus dexmedetomidine was compared with treatment with levo-
bupivacaine alone (Table III). In addition, the time required for
recovery of normal sensory function (sensory score ¼ 0) and
motor function (motor score ¼ 0) were similar in treatment with
levobupivacaine plus dexmedetomidine when compared with
treatment with levobupivacaine alone.n ¼ 8) Group 4 (n ¼ 8) Group 5 (n ¼ 8) P Value
13 (8–17) 13 (7–16)
)† 17 (12–25) 14 (7–19) 0.0001
)† 16 (8–18) 14 (6–21) 0.0004
) 15 (9–17) 13 (8–18) NS
) 17 (10–20) 14 (10–19) NS
) 17 (10–21) 13 (8–16) NS
) 18 (11–24) 14 (11–22) NS
) 15 (12–18) 15 (8–22) NS
) 16 (12–19) 14 (10–19) NS
bcutaneous saline, Group 3: perineural levobupivacaine (0.2 mL 0.5% solution) plus
cutaneous saline, Group 4: perineural saline and subcutaneous dexmedetomidine,
Table III
Sensory blockade scoresn for drugs, by group.†
Time
(min)
Group 1
(n ¼ 8)
Group 2
(n ¼ 8)
Group 3
(n ¼ 8)
Group 4
(n ¼ 8)
Group 5
(n ¼ 8)
Median (minimum–maximum)
30 0 (0–0) 2 (1–2) 2 (2–2) 1 (0–1) 0 (0–0)
60 0 (0–0) 2 (0–2) 2 (1–2) 1 (0–1) 0 (0–0)
90 0 (0–0) 2 (2–2) 2 (1–2) 1 (0–1) 0 (0–0)
120 0 (0–0) 2 (1–2) 2 (1–2) 0 (0–0) 0 (0–0)
150 0 (0–0) 1 (1–2) 1 (2–1) 0 (0–0) 0 (0–0)
180 0 (0–0) 1 (1–2) 1 (2–1) 0 (0–0) 0 (0–0)
210 0 (0–0) 1 (1–2) 1 (2–1) 0 (0–0) 0 (0–0)
240 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
n Sensory scores (complete blockade sensory score ¼ 3; normal sensory
function ¼ 0).
† Group 1: sham, Group 2: perineural levobupivacaine (0.2 mL 0.5% solution)
and subcutaneous saline, Group 3: perineural levobupivacaine (0.2 mL 0.5%
solution) plus dexmedetomidine (0.2 mL 0.5% levobupivacaine + 20 mg/kg
dexmedetomidine) and subcutaneous saline, Group 4: perineural saline and
subcutaneous dexmedetomidine, Group 5: perineural saline and subcutaneous
Table IV
Motor blockade scoresn for drugs, by group.†
Time
(min)
Group 1
(n ¼ 8)
Group 2
(n ¼ 8)
Group 3
(n ¼ 8)
Group 4
(n ¼ 8)
Group 5
(n ¼ 8)
Median (minimum–maximum)
30 0 (0–0) 2 (1–2) 2 (2–2) 1 (0–1) 0 (0–0)
60 0 (0–0) 2 (0–2) 2 (1–2) 1 (0–1) 0 (0–0)
90 0 (0–0) 2 (2–2) 2 (1–3) 0 (0–1) 0 (0–0)
120 0 (0–0) 1 (1–2) 1 (1–2) 0 (0–0) 0 (0–0)
150 0 (0–0) 1 (1–2) 1 (1–1) 0 (0–0) 0 (0–0)
180 0 (0–0) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0)
210 0 (0–0) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0)
240 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
n Sensory scores (complete blockade sensory score ¼ 3; normal sensory
function ¼ 0).
† Group 1: sham, Group 2: perineural levobupivacaine (0.2 mL 0.5% solution)
and subcutaneous saline, Group 3: perineural levobupivacaine (0.2 mL 0.5%
solution) plus dexmedetomidine (0.2 mL 0.5% levobupivacaine + 20 mg/kg
dexmedetomidine) and subcutaneous saline, Group 4: perineural saline and
subcutaneous dexmedetomidine, Group 5: perineural saline and subcutaneous
saline.
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α2-Adrenoceptors are expressed in the CNS and peripheral
tissues, including sympathetic nerve endings, neurons, vascular
smooth muscles, and platelets;7 however, the analgesic effect of
peripheral receptors have not been studied in the periphery.8
Agonists for the α2-adrenoceptor exert analgesic effects on the
CNS.26 The mechanism of action of dexmedetomidine in the CNS
was reduced, because dexmedetomidine inhibits the activity of rat
hypothalamic paraventricular nucleus neurons and paraventricular
nucleus parvocellular neurons.27
One of the important ﬁndings of our study is that the dexme-
detomidine and levobupivacaine group showed signiﬁcantly more
analgesic status than the levobupivacaine alone group, according
to both hot-plate and tail-ﬂick test results. This beneﬁcial effect
was dominant especially at 30 and 60 minutes parallel to the
drug’s pharmacokinetics. Although there is no difference between
the control and local anesthesia group according to the hot-plate
and tail-ﬂick test results at 490 minutes, in fact this is an
unexpected result according to the drug’s half-time. However, as
shown in Table III and Table IV sensory and motor blockadecontinue until 240 and 180 minutes, respectively. There is
no literature to explain this circumstance. One possible explan-
ation is the well-known phenomenon that the nerves related with
pain—such as Aδ and C ﬁbers—is blocked earlier than motor
functions.28
Another important ﬁnding of our study is that the dose of
dexmedetomidine used did not increase the duration of the
sensory and motor blockades when added to levobupivacaine.
Nor did subcutaneous dexmedetomidine increase the duration of
sensory analgesia. Our administered dose of subcutaneous dexme-
detomidine was too low to induce a central analgesic effect;
previous studies have shown that dexmedetomidine at a dose of
144 mg/kg exerts a central analgesic effect.8,29 Previous studies
have indicated that high doses of perineural dexmedetomidine
(28–40 mg/kg) added to ropivacaine and bupivacaine increases the
duration of sensory and motor blockades in rats.14,16 On the
contrary, in our study, the combination of dexmedetomidine (20
mg/kg) and levobupivacaine did not increase the duration of the
sensory and motor blockade when compared with the levobupi-
vacaine alone. One of the possible explanations of this result is that
the duration of sensory and motor blockade is strongly related to
the dosage of dexmedetomidine. It has been reported that using
clonidine in peripheral nerve blocks, similar to dexmedetomidine,
can cause centrally mediated analgesia, α2-adrenoceptor-mediated
vasoconstrictive effects, inﬂammatory responses, and direct activ-
ities on the peripheral nerve. Also, Brummett et al1 reported that
clonidine enhances activity-dependent hyperpolarization by
blocking the hyperpolarization-activated current. It is well estab-
lished that clonidine is a postoperative analgesia with an activity-
dependent inhibition of inwardly rectifying potassium currents.
Moreover, α2-adrenoceptors have a vasoconstriction effect in the
periphery; however, the vasoconstrictive properties of clonidine
are weaker than that of adrenaline.30 Based on this relationship,
Brummett et al1 declared that unlike adrenaline, the enhancement
of the sensory blockage by clonidine is not attenuated by the
coadministration of α-adrenoceptor antagonists.31,32Limitations
In our study, the evaluation of motor block and the paw thrust
measures used were limited to subjective assessments that were
adopted based on measures described in previous studies.14
Systemic administration of dexmedetomidine provided analgesia
and sedation because high doses of perineural dexmedetomidine
could be absorbed, thereby mediating a central effect that might
also cause sensory and motor blockades. However, the doses used
in this study were too low for use in human studies. We speculate
that high doses of dexmedetomidine combined with levobupiva-
caine could render an increased duration of sensory and motor
blockades. Because of our limited facilities, we used ketamine for
anesthesia instead of inhaler anesthesia in this study. This is in
accordance with previous studies.Conclusions
Dexmedetomidine combined with levobupivacaine did not
increase the duration of the sensory and motor blockade at a dose
of 20 mg/kg. However, dexmedetomidine combined with levobu-
pivacaine increased the quality of analgesia in rats. Thus, we
propose that drug combinations be used in clinical practice to
achieve stable analgesia. Furthermore, our results can be used as a
guide for future studies in human beings.
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